Real-World Management of AEs with ALK Inhibitors
Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, discussing unique challenges and benefits observed in clinical practice.
Video content above is prompted by the following:
- Based on your experience, how does the adverse event profile of lorlatinib compare to those of other ALK inhibitors like alectinib or brigatinib?
- Are there any unique challenges or benefits you've observed?
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making
March 18th 2016Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).
